| Drug General Information |
| Drug ID |
D0Y9EW
|
| Former ID |
DNAP001683
|
| Drug Name |
Vemurafenib
|
| Synonyms |
PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor)
|
| Drug Type |
Small molecular drug
|
| Indication |
Metastatic melanoma; Thyroid cancer [ICD9: 172, 140-229, 193; ICD10:C43, C73]
|
Approved |
[1],
[2],
[3]
|
|---|
| Company |
Daiichi Sankyo group; Genentech
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C23H18ClF2N3O3S
|
| InChI |
InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)
|
| InChIKey |
GPXBXXGIAQBQNI-UHFFFAOYSA-N
|
| CAS Number |
CAS 918504-65-1
|
| PubChem Compound ID |
|
| PubChem Substance ID |
86450036, 99207986, 99344329, 99436933, 104245715, 123055406, 123393726, 124757131, 125163935, 125240992, 125312523, 125477821, 126731467, 131408691, 131480743, 134213431, 135267495, 135360056, 135611115, 135626717, 135686206, 135686207, 135686222, 135686223, 135727433, 136367377, 136920367, 137241152, 137275900, 138196197, 152258377, 160647214, 160837190, 162011358, 162037528, 162201724, 163098027, 163345507, 163390276, 164041819, 164193918, 164766097, 164834160, 165826640, 170483525, 170498105, 172087033, 172914376, 174531480, 175267423
|
| ChEBI ID |
ChEBI:63637
|
| SuperDrug ATC ID |
L01XE15
|
| Drug Resistance Mutation (DRM) |
| DRM |
DRM Info
|
| Target and Pathway |
| Target(s) |
B-Raf proto-oncogene serine/threonine-protein kinase |
Target Info |
Modulator |
[3]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
FoxO signaling pathway
|
|
mTOR signaling pathway
|
|
Vascular smooth muscle contraction
|
|
Focal adhesion
|
|
Natural killer cell mediated cytotoxicity
|
|
Long-term potentiation
|
|
Neurotrophin signaling pathway
|
|
Serotonergic synapse
|
|
Long-term depression
|
|
Regulation of actin cytoskeleton
|
|
Insulin signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Alcoholism
|
|
Hepatitis C
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
Colorectal cancer
|
|
Renal cell carcinoma
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Thyroid cancer
|
|
Melanoma
|
|
Bladder cancer
|
|
Chronic myeloid leukemia
|
|
Acute myeloid leukemia
|
|
Non-small cell lung cancer
|
|
NetPath Pathway
|
IL-7 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Integrin signalling pathway
|
|
Interleukin signaling pathway
|
|
PDGF signaling pathway
|
|
T cell activation
|
|
VEGF signaling pathway
|
|
Ras Pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
CDC42 signaling events
|
|
mTOR signaling pathway
|
|
Ras signaling in the CD4+ TCR pathway
|
|
ErbB1 downstream signaling
|
|
PDGFR-beta signaling pathway
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Trk receptor signaling mediated by the MAPK pathway
|
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
|
Reactome
|
Spry regulation of FGF signaling
|
|
Frs2-mediated activation
|
|
ARMS-mediated activation
|
|
CREB phosphorylation through the activation of Ras
|
|
RAF activation
|
|
MAP2K and MAPK activation
|
|
Negative feedback regulation of MAPK pathway
|
|
Negative regulation of MAPK pathway
|
|
WikiPathways
|
Serotonin Receptor 4/6/7 and NR3C Signaling
|
|
Serotonin HTR1 Group and FOS Pathway
|
|
Estrogen signaling pathway
|
|
Senescence and Autophagy in Cancer
|
|
Regulation of Actin Cytoskeleton
|
|
EGF/EGFR Signaling Pathway
|
|
MAPK Cascade
|
|
MAPK Signaling Pathway
|
|
Focal Adhesion
|
|
Bladder Cancer
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
Polycystic Kidney Disease Pathway
|
|
Corticotropin-releasing hormone
|
|
B Cell Receptor Signaling Pathway
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Signaling by FGFR
|
|
NGF signalling via TRKA from the plasma membrane
|
|
Integrin-mediated Cell Adhesion
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01898585) An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma. U.S. National Institutes of Health. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5893). |
|---|
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
|---|
